Northwest Coalition for Responsible Investment
Leading Maker of HIV Drugs First to Join Patent Pool
In July, Gilead Sciences became the first pharmaceutical company to join the Medicines Patent Pool. By making licenses available for vital HIV and Hepatitis B drugs, shareholders note that Gilead shows uncommon leadership and sets an example for the entire industry.
Said Judy Byron, OP, of the Northwest Coalition for Responsible Investment, “In 2004, when the Northwest Coalition for Responsible Investment (NWCRI) and ICCR shareholders asked Gilead Sciences to make its key HIV medicines accessible in developing countries where HIV/AIDS was now a pandemic, senior management committed to do this. Over the years Gilead Sciences has fulfilled its commitment through voluntary licenses, the first fixed-dose combination drug for HIV, and pediatric formulations. Today, we commend Gilead Sciences for its continuing leadership in global health.”
Shareholders Applaud Gilead Sciences Licensing Agreement with the Medicines Patent Pool
Gilead Expands Access Program for Medications in Developing World
2010-2011 Shareholder Season
Each year NWCRI and ICCR members press companies to be socially and environmentally responsible by sponsoring over 300 shareholder resolutions on major social and environmental issues.
| NWCRI Resolutions & Dialogues ICCR Resolutions |
Seattle, WA 98115